100393-41-7

Usage

Uses

Used in Chemical and Biochemical Research:
3-Amino-3-Naphthalen-1-yl-Propionic Acid is used as a research compound for its unique properties. It is employed in various chemical and biochemical studies to explore its potential applications and interactions with other compounds.
Used in Pharmaceutical Development:
Although the specifics of 3-AMINO-3-NAPHTHALEN-1-YL-PROPIONIC ACID's usage or any potential health effects are not widely available, 3-Amino-3-Naphthalen-1-yl-Propionic Acid may be used as a starting material or intermediate in the development of pharmaceuticals. Additional research is required to fully understand 3-AMINO-3-NAPHTHALEN-1-YL-PROPIONIC ACID's utility and safety profile in the context of drug development.
Used in Material Science:
3-Amino-3-Naphthalen-1-yl-Propionic Acid may also be used in material science for the development of new materials with specific properties. 3-AMINO-3-NAPHTHALEN-1-YL-PROPIONIC ACID's ability to form complexes with other substances can be exploited to create materials with tailored characteristics for various applications. Further research is needed to explore these possibilities and understand the full potential of 3-AMINO-3-NAPHTHALEN-1-YL-PROPIONIC ACID in material science.

InChI:InChI=1/C13H13NO2/c14-12(8-13(15)16)11-7-3-5-9-4-1-2-6-10(9)11/h1-7,12H,8,14H2,(H,15,16)/t12-/m1/s1

Upstream product

• 141-82-2 malonic acid 
• 66-77-3 1-naphthaldehyde 

Downstream Products

• 275826-46-5 (S)-3-amino-3-(1-naphthyl)propionic acid 

Relevant academic research and scientific papers

Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes

The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.

SYNTHESIS OF 6-ARYL-4-HYDROXYPIPERIDIN-2-ONES AND A POSSIBLE APPLICATION TO THE SYNTHESIS OF A NOVEL HMG-CoA REDUCTASE INHIBITOR

A series of 6-aryl-4-hydroxypiperidin-2-ones (11a-11g) were synthesised with the key step being a Dieckmann cyclisation of the appropriate methyl 3-(ethoxycarbonylacetylamino)-3-(substituted) propionate (8a-8g) and this new synthetic route was successfully applied to the synthesis of 4-hydroxy-6-(2-phenylethyl)piperidin-2-one (11h).The application of this strategy to the synthesis of the putative HMG-CoA reductase inhibitor 6--4-hydroxypiperidin-2-one (11i) was attempted, but failed during the Dieckmann cyclisation of methyl 3-(ethoxycarbonylacetylamino)- 3-propionate (8i).An alternative synthesis of a 1:1 diastereomeric mixture of (11i) was achieved by the reductive cleavage of the isoxazoline (24) with Raney nickel.The mixture of diastereoisomers (11i) was inactive in-vitro and in-vivo (rat) against HMG-CoA reductase